0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters |

Update on Risk of Endophthalmitis After Intravitreal Drug Injections and Potential Impact of Elimination of Topical Antibiotics

Abdhish R. Bhavsar, MD; Cynthia R. Stockdale, MSPH; Frederick L. Ferris, MD; Alexander J. Brucker, MD; Neil M. Bressler, MD; Adam R. Glassman, MS; for the Diabetic Retinopathy Clinical Research Network
Arch Ophthalmol. 2012;130(6):809-810. doi:10.1001/archophthalmol.2012.227.
Text Size: A A A
Published online

Extract

Previously, the Diabetic Retinopathy Clinical Research Network reported a low rate of endophthalmitis achieved after intravitreal injection via a protocol requiring topical povidone-iodine, a sterile eyelid speculum, and topical anesthetic and not requiring topical antibiotics, sterile gloves, or a sterile drape.1 These results included 3838 injections of either ranibizumab or preservative-free triamcinolone acetonide. No antibiotics were given either before or after the injections in 1276 eyes. Of 3226 ranibizumab injections given between 2 Diabetic Retinopathy Clinical Research Network randomized trials, 3 cases of endophthalmitis occurred, all in eyes receiving topical antibiotics for several days after the injection.

Topics

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment
Endophthalmitis in intravitral injections
Posted on July 22, 2012
Ramesh Sivaraj
Heart of England NHS Foundation Trust
Conflict of Interest: None Declared
Dear Dr Bhavsar et al,Thank you for your article. I was wondering if you encountered any patients with iodine allergy as these patients cannot have povidone prophylaxis preceding an intravitreal injection. There are some reports mentioning documented iodine allergy is not a contraindication for povidone use1. Is there a subgroup of your patients which did not receive povidone and if so did that influence the incidence of endophthalmitis.1. http://www.retinalphysician.com/articleviewer.aspx?articleid=1034552. Caldwell DR, Kastl PR, Cook J, Simon J. Povidone-iodine: its efficacy as a preoperative conjunctival and periocular preparation. Ann Ophthalmol. 1984;16: 577, 580.3. Apt L, Isenberg S, Yoshimori R, Paez JH. Chemical preparation of the eye In ophthalmic surgery. III. Effect of povldone-iodlne on the conjunctiva. Arch Ophthalmol. 1984;102:728-729.4. Isenberg SJ, Apt L, Yoshimorl R, Khwarg S. Chemical preparation of the eye In ophthalmic surgery. IV Comparison of povldone-iodlne on the conjunctiva with a prophylactic antibiotic. Arch Ophthalmol. 1985;103:1340-1342.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

507 Views
31 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();